AKBA stock icon

Akebia Therapeutics
AKBA

$1.12
2.59%
 

About: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Employees: 167

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

215% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 13

44% more capital invested

Capital invested by funds: $72.7M [Q4 2023] → $104M (+$31.7M) [Q1 2024]

33% more funds holding

Funds holding: 86 [Q4 2023] → 114 (+28) [Q1 2024]

25% more call options, than puts

Call options by funds: $1.7M | Put options by funds: $1.36M

13% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 24

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

1.82% less ownership

Funds ownership: 29.07% [Q4 2023] → 27.24% (-1.82%) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
346%
upside
Avg. target
$5.5
391%
upside
High target
$6
436%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Ed Arce
436%upside
$6
Buy
Maintained
28 Mar 2024
HC Wainwright & Co.
Ed Arce
346%upside
$5
Buy
Reiterated
15 Mar 2024

Financial journalist opinion